ArticleJournal of clinical microbiology2010
In vitro susceptibility of the yeast pathogen cryptococcus to fluconazole and other azoles varies with molecular genotype.
Article in Journal of clinical microbiology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 83 citations in OpenAlex.
- In vitro evidence to support amphotericin B and flucytosine combination therapy for talaromycosis.PLoS neglected tropical diseases · 2025Article
- Genetic diversity and antifungal susceptibilities of environmental Cryptococcus neoformans and Cryptococcus gattii species complexes.IMA fungus · 2024Article
- Reduced Susceptibility to Azoles in Cryptococcus gattii Correlates with the Substitution R258L in a Substrate Recognition Site of the Lanosterol 14-α-Demethylase.Microbiology spectrum · 2023Article
- Distribution and Polymorphisms of Group I Introns in Mitochondrial Genes fromJournal of fungi (Basel, Switzerland) · 2023Article
- Article
- Antifungal susceptibility of clinical Cryptococcus gattii isolates from Colombia varies among molecular types.Medical mycology · 2021Article
- Diagnostic and therapeutic management of Cryptococcosis in a kitten with practical considerations to veterinary pediatric therapeutic approach.Medical mycology case reports · 2021Article
- Molecular epidemiology and antifungal susceptibilities of Cryptococcus species isolates from HIV and non-HIV patients in Southwest China.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2021Article
- The Antifungal and Synergistic Effect of Bisphosphonates inAntimicrobial agents and chemotherapy · 2021Article
- A case ofIDCases · 2021Article
- Implementation of MALDI-TOF Mass Spectrometry and Peak Analysis: Application to the Discrimination ofJournal of fungi (Basel, Switzerland) · 2020Article
- Article
- Identification of the environmental source of infection for a domestic ferret with cryptococcosis.Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc · 2019Article
- Central Nervous System Cryptococcal Infections in Non-HIV Infected Patients.Journal of fungi (Basel, Switzerland) · 2019Review
- Article
- Therapy of Non-Dermatophytic Mycoses in Animals.Journal of fungi (Basel, Switzerland) · 2018Review
- Article
- Article
- Polymorphism in Mitochondrial Group I Introns amongFrontiers in microbiology · 2018Article
- Equine Pulmonary Cryptococcosis: A Comparative Literature Review and Evaluation of Fluconazole Monotherapy.Mycopathologia · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cryptococcosis is primarily caused by Cryptococcus neoformans and Cryptococcus gattii. These two pathogenic species each divide into four distinct molecular genotypes. In this study, we examined whether genotype influenced susceptibility to antifungal drugs used to treat cryptococcosis using the broth microdilution method described by the Clinical and Laboratory Standards Institute. C. gattii isolates belonging to molecular genotype VGII had significantly higher MIC values for flucytosine and all azole antifungal agents tested, particularly fluconazole, than isolates of other C. gattii genotypes. In an extended analysis of fluconazole susceptibility, VGII isolates from the north and west of Australia required higher drug levels for inhibition than those from Vancouver Island, Canada. Within C. neoformans, genotype VNII had significantly lower geometric mean MICs for fluconazole than genotype VNI. These results indicate that cryptococcal species, molecular genotype, and region of origin may be important when deciding treatment options for cryptococcosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.